rare disease

Immedica to Acquire Biopharma Company Marinus

Stockholm, Sweden-headquartered global rare disease company Immedica Pharma has agreed to acquire Marinus Pharmaceuticals, a US commercial-stage pharmaceutical company developing therapies for seizure disorders, for enterprise value of approximately $151 million.

News

Pfizer Doubles Dublin Biologicals Capacity

Pfizer has announced plans to invest more than €1.2 billion at its site in Grange Castle, Dublin, Ireland, to double capacity for biological drug substances.

Topics • Strategy

After Pharma’s Patent Cliff

Top-Feature

Evonik Industries AG

Safer, Scalable Pharmaceutical Manufacturing with Flow Chemistry

CHEManager International c/o Wiley-VCH GmbH

Upcoming Virtual Events

SCIEX

Capillary Electrophoresis in Biotherapeutic Development: Platform Methods, Fragment Workflows, and ADC Characterization

INOSIM GmbH

Predictive Simulation in Pharma Production

Agilent Technologies Inc.

Comprehensive Insights into Antibody–Drug Conjugates (ADC) for Precision Cancer Therapy

Citrine

Operationalizing AI in Polymer Development: How Syensqo Is Scaling Impact with the Citrine Platform

Global Impact Coalition (GIC)

Siemens Joins the Global Impact Coalition

Article

Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

SchüllerConsulting

Immedica Pharma AB